For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista brasileira de hematologia e hemoterapia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331 |
Resumo: | Abstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival. |
id |
ABHHTC-1_df5551b342b5f862e3dc94717a0e303d |
---|---|
oai_identifier_str |
oai:scielo:S1516-84842017000400331 |
network_acronym_str |
ABHHTC-1 |
network_name_str |
Revista brasileira de hematologia e hemoterapia (Online) |
repository_id_str |
|
spelling |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remissionAbnormal protein bandOligoclonal bandsMultiple myelomaPrognosisAbstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2017-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331Revista Brasileira de Hematologia e Hemoterapia v.39 n.4 2017reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2017.05.010info:eu-repo/semantics/openAccessSilva,Luiza Soares Vieira daCrusoe,Edvan de QueirozSouza,Lais Rocha Guimarães deChiattone,Carlos SérgioHungria,Vânia Tietsche de Moraeseng2017-12-08T00:00:00Zoai:scielo:S1516-84842017000400331Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2017-12-08T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false |
dc.title.none.fl_str_mv |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
title |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
spellingShingle |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission Silva,Luiza Soares Vieira da Abnormal protein band Oligoclonal bands Multiple myeloma Prognosis |
title_short |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
title_full |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
title_fullStr |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
title_full_unstemmed |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
title_sort |
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission |
author |
Silva,Luiza Soares Vieira da |
author_facet |
Silva,Luiza Soares Vieira da Crusoe,Edvan de Queiroz Souza,Lais Rocha Guimarães de Chiattone,Carlos Sérgio Hungria,Vânia Tietsche de Moraes |
author_role |
author |
author2 |
Crusoe,Edvan de Queiroz Souza,Lais Rocha Guimarães de Chiattone,Carlos Sérgio Hungria,Vânia Tietsche de Moraes |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Silva,Luiza Soares Vieira da Crusoe,Edvan de Queiroz Souza,Lais Rocha Guimarães de Chiattone,Carlos Sérgio Hungria,Vânia Tietsche de Moraes |
dc.subject.por.fl_str_mv |
Abnormal protein band Oligoclonal bands Multiple myeloma Prognosis |
topic |
Abnormal protein band Oligoclonal bands Multiple myeloma Prognosis |
description |
Abstract Background: The emergence of oligoclonal bands, proteins differing from those originally identified at diagnosis, has been reported in multiple myeloma patients after high-dose chemotherapy followed by autologous stem cell transplantation and after successful conventional chemotherapy. The clinical relevance of oligoclonal bands remains unclear, but their emergence has been associated with better prognosis. The aim of the present study was to determine the prevalence, clinical characteristics and prognostic impact of the presence of oligoclonal bands in multiple myeloma patients. Methods: A retrospective cohort study was conducted. The study included newly diagnosed multiple myeloma patients with at least very good partial response after conventional dose or high-dose chemotherapy followed by autologous stem cell transplantation. The emergence of oligoclonal bands was identified using serum protein electrophoresis as well as serum and urine immunofixation techniques. Results: A total of 101 patients were included with a median follow-up of 42 months. In total, 55% were male, and the median age was 58 years (29-87 years). Fifty-one (50.5%) patients developed oligoclonal bands. They comprised 60% (45/75) of patients treated with autologous stem cell transplantation and 23% (6/26) of those who were not transplanted. Patients with oligoclonal bands showed better progression-free survival than those without the emergence of oligoclonal bands (p-value = 0.0075). Conclusion: The prevalence of oligoclonal bands in this study population was 50.5% with its frequency being greater in cases treated with autologous stem cell transplantation and in those attaining complete remission. Complete remission was more important than the emergence of oligoclonal bands on progression-free survival. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842017000400331 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjhh.2017.05.010 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
publisher.none.fl_str_mv |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular |
dc.source.none.fl_str_mv |
Revista Brasileira de Hematologia e Hemoterapia v.39 n.4 2017 reponame:Revista brasileira de hematologia e hemoterapia (Online) instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) instacron:ABHHTC |
instname_str |
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
instacron_str |
ABHHTC |
institution |
ABHHTC |
reponame_str |
Revista brasileira de hematologia e hemoterapia (Online) |
collection |
Revista brasileira de hematologia e hemoterapia (Online) |
repository.name.fl_str_mv |
Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC) |
repository.mail.fl_str_mv |
sbhh@terra.com.br||secretaria@rbhh.org |
_version_ |
1754213112991449088 |